Cargando…

Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States

BACKGROUND: Limited data are available on health care resource utilization (HCRU) and health care costs of calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) for preventive treatment of migraine. OBJECTIVE: To compare all-cause and migraine-related HCRU and direct health care costs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varnado, Oralee J, Manjelievskaia, Janna, Ye, Wenyu, Perry, Allison, Schuh, Kory, Wenzel, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373045/ https://www.ncbi.nlm.nih.gov/pubmed/35876297 http://dx.doi.org/10.18553/jmcp.2022.28.8.818

Ejemplares similares

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
por: Ocheretyaner, Eric R, et al.
Publicado: (2022)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
por: Shah, Tulsi, et al.
Publicado: (2023)

Commentary: Calcitonin Gene Related Peptide and Its Clinical Utility for the Treatment of Traumatic Brain Injury, Subarachnoid Hemorrhage and Associated Migraine
por: Mehkri, Yusuf, et al.
Publicado: (2022)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019)

Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis
por: Huang, Tingting, et al.
Publicado: (2022)

Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
por: Thieu, Vivian T., et al.
Publicado: (2020)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis
por: Zhang, Zizhen, et al.
Publicado: (2021)

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
por: Breen, Ilana D., et al.
Publicado: (2021)

Alpha-Calcitonin Gene Related Peptide: New Therapeutic Strategies for the Treatment and Prevention of Cardiovascular Disease and Migraine
por: Kumar, Ambrish, et al.
Publicado: (2022)

Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review
por: Jiang, Yan, et al.
Publicado: (2022)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
por: Fila, Michal, et al.
Publicado: (2022)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment
por: Tfelt-Hansen, Peer C.
Publicado: (2009)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
por: Lu, Jiajie, et al.
Publicado: (2021)

Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks
por: Han, Dawei
Publicado: (2019)

The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
por: Iyengar, Smriti, et al.
Publicado: (2017)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
por: Lassen, L. H., et al.
Publicado: (2008)

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
por: Holzer, Peter, et al.
Publicado: (2022)

Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor
por: Gupta, Pragya, et al.
Publicado: (2021)

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
por: Mackenzie, Kimberly D., et al.
Publicado: (2022)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review
por: Pervez, Hira, et al.
Publicado: (2020)

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines
por: Katsuki, Masahito, et al.
Publicado: (2023)

Calcitonin Gene-Related Peptide and Adrenomedullin Levels During Ictal and Interictal Periods in Patients With Migraine
por: Neyal, Abdurrahman, et al.
Publicado: (2023)

Evaluation of Plasma Calcitonin Gene-Related Peptide as a Biomarker for Painful Temporomandibular Disorder and Migraine
por: Tchivileva, Inna E, et al.
Publicado: (2023)

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study
por: Kawata, Ariane K., et al.
Publicado: (2021)

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
por: Fernández-Bravo-Rodrigo, Jaime, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis
por: Chen, Yao-Yao, et al.
Publicado: (2021)

Editorial: Calcitonin Gene-Related Peptide: Novel Biology and Treatments
por: Brain, Susan D., et al.
Publicado: (2022)

The Calcitonin/Calcitonin Gene-Related Peptide Family in Invertebrate Deuterostomes
por: Sekiguchi, Toshio
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_86o1432bl5pantfehjretpjlo7